SillaJen, Inc. (215600.KQ)
KRW 2565.0
(0.79%)
KRW 2565.0
(0.79%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.11 Billion KRW | -10.0% |
| 2022 | 5.68 Billion KRW | 83.92% |
| 2021 | 3.08 Billion KRW | -81.76% |
| 2020 | 16.93 Billion KRW | 173.53% |
| 2019 | 6.18 Billion KRW | -10.19% |
| 2018 | 6.89 Billion KRW | 27.53% |
| 2017 | 5.4 Billion KRW | 24.16% |
| 2016 | 4.35 Billion KRW | 52.64% |
| 2015 | 2.85 Billion KRW | -28.59% |
| 2014 | 3.99 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 670.21 Million KRW | -54.13% |
| 2024 Q2 | 1.9 Billion KRW | 183.68% |
| 2023 Q3 | 1.74 Billion KRW | -18.37% |
| 2023 FY | 5.11 Billion KRW | -10.0% |
| 2023 Q4 | 1.46 Billion KRW | -16.11% |
| 2023 Q1 | 909.56 Million KRW | -57.39% |
| 2023 Q2 | 2.13 Billion KRW | 134.57% |
| 2022 Q2 | 1.28 Billion KRW | 90.54% |
| 2022 FY | 5.68 Billion KRW | 83.92% |
| 2022 Q1 | 675.34 Million KRW | -56.23% |
| 2022 Q4 | 2.13 Billion KRW | -5.91% |
| 2022 Q3 | 2.26 Billion KRW | 76.32% |
| 2021 Q2 | 795.67 Million KRW | 120.38% |
| 2021 Q4 | 1.54 Billion KRW | 296.98% |
| 2021 FY | 3.08 Billion KRW | -81.76% |
| 2021 Q1 | 361.04 Million KRW | -92.7% |
| 2021 Q3 | 388.68 Million KRW | -51.15% |
| 2020 FY | 16.93 Billion KRW | 173.53% |
| 2020 Q4 | 4.94 Billion KRW | -64.19% |
| 2020 Q3 | 13.81 Billion KRW | -24.86% |
| 2020 Q2 | 18.38 Billion KRW | 69.83% |
| 2020 Q1 | 10.82 Billion KRW | -13.53% |
| 2019 Q3 | 13.89 Billion KRW | -81.27% |
| 2019 Q1 | 16.69 Billion KRW | 32.08% |
| 2019 FY | 6.18 Billion KRW | -10.19% |
| 2019 Q4 | 12.52 Billion KRW | -9.89% |
| 2019 Q2 | 74.2 Billion KRW | 344.62% |
| 2018 Q2 | 14.78 Billion KRW | -9.24% |
| 2018 Q4 | 12.63 Billion KRW | -35.36% |
| 2018 Q3 | 19.54 Billion KRW | 32.19% |
| 2018 FY | 6.89 Billion KRW | 27.53% |
| 2018 Q1 | 16.29 Billion KRW | -13.08% |
| 2017 Q2 | 18.79 Billion KRW | 53.6% |
| 2017 FY | 5.4 Billion KRW | 24.16% |
| 2017 Q1 | 12.23 Billion KRW | -68.23% |
| 2017 Q4 | 18.74 Billion KRW | 86.32% |
| 2017 Q3 | 10.06 Billion KRW | -46.48% |
| 2016 Q4 | 38.52 Billion KRW | 186.77% |
| 2016 Q2 | 10.31 Billion KRW | 11.79% |
| 2016 Q1 | 9.22 Billion KRW | -43.48% |
| 2016 FY | 4.35 Billion KRW | 52.64% |
| 2016 Q3 | 13.43 Billion KRW | 30.22% |
| 2015 Q3 | 7.84 Billion KRW | -44.4% |
| 2015 Q4 | 16.32 Billion KRW | 108.05% |
| 2015 Q2 | 14.11 Billion KRW | 38.43% |
| 2015 Q1 | 10.19 Billion KRW | -21.86% |
| 2015 FY | 2.85 Billion KRW | -28.59% |
| 2014 FY | 3.99 Billion KRW | 0.0% |
| 2014 Q2 | 192.97 Million KRW | -94.32% |
| 2014 Q3 | 5.84 Billion KRW | 2931.18% |
| 2014 Q4 | 13.04 Billion KRW | 123.06% |
| 2014 Q1 | 3.39 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 95.352% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | 34.841% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 90.818% |
| Bioneer Corporation | 204.55 Billion KRW | 97.501% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | 33.952% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 92.173% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | 84.207% |
| Helixmith Co., Ltd | 37.36 Billion KRW | 86.319% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 98.212% |
| Medy-Tox Inc. | 110.88 Billion KRW | 95.39% |
| Peptron, Inc. | 16.65 Billion KRW | 69.308% |
| Amicogen, Inc. | 52.82 Billion KRW | 90.322% |
| Genexine, Inc. | 41.62 Billion KRW | 87.719% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | 68.378% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 94.816% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 87.511% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 94.284% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | 80.08% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | 85.497% |
| Genomictree Inc. | 16.26 Billion KRW | 68.569% |
| MedPacto, Inc. | 26.91 Billion KRW | 81.009% |
| D&D Pharmatech | 32.16 Billion KRW | 84.105% |
| EASY BIO,Inc. | 29.67 Billion KRW | 82.771% |
| GI Innovation, Inc. | 57.59 Billion KRW | 91.123% |